 Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. NASDAQ: EVGN TASE: EVGN, announced today that it has entered a service agreement with Biose Industrie, a France based CDMO, for the scale-up production of its drug candidates, microbial consortia BMC121 BMC127 for its Immuno-Oncology program. This agreement will accelerate the Companys Immuno-Oncology program which is currently planned to enter the clinic in 2021 for proof of concept studies. 